FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $37.11 million. The enterprise value is $39.21 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 100.77 million shares outstanding. The number of shares has increased by 3.41% in one year.
| Current Share Class | 100.77M |
| Shares Outstanding | 100.77M |
| Shares Change (YoY) | +3.41% |
| Shares Change (QoQ) | +0.68% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 39.14% |
| Float | 93.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| Forward PS | 0.25 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28
| Current Ratio | 1.28 |
| Quick Ratio | 0.98 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -20.53% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $370,401 |
| Profits Per Employee | -$250,603 |
| Employee Count | 486 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 6.04 |
Taxes
| Income Tax | -137,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.65% in the last 52 weeks. The beta is 0.73, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -38.65% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 51.19 |
| Average Volume (20 Days) | 1,601,635 |
Short Selling Information
The latest short interest is 4.32 million, so 4.29% of the outstanding shares have been sold short.
| Short Interest | 4.32M |
| Short Previous Month | 4.03M |
| Short % of Shares Out | 4.29% |
| Short % of Float | 4.65% |
| Short Ratio (days to cover) | 3.27 |
Income Statement
In the last 12 months, FibroGen had revenue of $180.02 million and -$121.79 million in losses. Loss per share was -$1.22.
| Revenue | 180.02M |
| Gross Profit | -15.16M |
| Operating Income | -119.04M |
| Pretax Income | -168.39M |
| Net Income | -121.79M |
| EBITDA | -114.82M |
| EBIT | -119.04M |
| Loss Per Share | -$1.22 |
Full Income StatementBalance Sheet
The company has $131.00 million in cash and $92.98 million in debt, giving a net cash position of $38.03 million or $0.38 per share.
| Cash & Cash Equivalents | 131.00M |
| Total Debt | 92.98M |
| Net Cash | 38.03M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | -201.70M |
| Book Value Per Share | -2.42 |
| Working Capital | 54.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$125.85 million and capital expenditures -$376,000, giving a free cash flow of -$126.23 million.
| Operating Cash Flow | -125.85M |
| Capital Expenditures | -376,000 |
| Free Cash Flow | -126.23M |
| FCF Per Share | -$1.25 |
Full Cash Flow StatementMargins
Gross margin is -8.42%, with operating and profit margins of -66.13% and -67.66%.
| Gross Margin | -8.42% |
| Operating Margin | -66.13% |
| Pretax Margin | -67.73% |
| Profit Margin | -67.66% |
| EBITDA Margin | -63.78% |
| EBIT Margin | -66.13% |
| FCF Margin | -116.79% |